Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (2325)	2/22/2018 7:05:08 PM
From: Miljenko Zuanic	Respond to of 3559

My guess would be PD-L1 positive (>1%), to close mimic K-189 trial (regardless PD-L1 expression has sub-population with positive PD-L1). Need protocol to figure out what are their intention. They can use 300 mg 3W-schedule for REGN2810, so trial can be executed fast, and be fully blinded.

To: DewDiligence_on_SI who wrote (2325)	5/3/2018 4:55:41 PM
From: Miljenko Zuanic	1 Recommendation Recommended By DewDiligence_on_SI Read Replies (2) \| Respond to of 3559

Now we know it is for >50% PDL1 expression, where Keyt become SOC. clinicaltrials.gov Still do not understand what they want to achieve by combining 2810 with Ipi, when their own anti-CTLA4-ab (REGN4659, files.shareholder.com is way behind. Also, no idea what dose/schedule for Ipi is in protocol, as well what is expectation??? In addition, from patent applications and animal study for in-house anti-CTLA-4 chombo, data are scarce.